COVID-19 is a novel virus and despite the
predilection for the respiratory tract, it has the potential of becoming a multi-systemic
disease. With its emergence arose the need for prompt and appropriate
diagnostic and prognostic molecular tests that cut across all sections of
laboratory medicine. A proper laboratory diagnosis is critical in order to aid
clinical management and control the disease transmission.
The ideal specimen for the detection of
SARS-CoV-2 is bronchoalveolar lavage but this is quite an invasive specimen to
obtain. There is a high risk of infecting the caregiver via aerosols generated
during the procedure. Instead, the WHO recommends nasal and oropharyngeal swabs
for routine testing using flocked nylon swabs. Lung biopsy is reserved for
post-mortem cases.
During sample collection, it is crucial
that appropriate personal protective equipment (PPE) is worn and that the
procedure is performed in a room with adequate ventilation. The best transport
medium is the viral transport medium (VTM) stored on ice.
Sample processing should be performed in a
biosafety level two (BSL-2) laboratory facility (or higher) due to the high
infectivity of the virus. The widely accepted test for the early detection of
SARS-CoV-2 RNA is the Nucleic Acid Amplification Test (NAAT) using reverse
transcriptase quantitative polymerase chain reaction (RT-qPCR). Other
modalities include antigen-based tests and viral cultures.
Concurrently, samples should also be
obtained for biochemical tests due to the “cytokine storm” associated with
severe COVID-19 infection. Hepatic and renal biomarkers including inflammatory
markers such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-α (TNF-α) should
be assayed as they could be elevated in severe manifestations of the disease.
The organ in the eye of the storm are the
lungs and they were extensively studied during the pandemic. In COVID-19
infection, they may grossly appear to be heavy, congested and edematous with
cut sections that show patchy areas of hemorrhage and focal areas of vascular
plugging. Generally, the pulmonary pathologic features appear to be consistent
with early/organizing diffuse alveolar damage (DAD).
The utility of laboratory tests for
screening, diagnosis, monitoring and prognostication of COVID-19 is central to
the management of this emerging infectious disease.
Author(s)
Details:
Khadija
Abimbola Abdulraheem
Department of Medical Microbiology, National
Hospital Abuja, Nigeria.
Richard
Kelechi Samuel
Histopathology Department, University of Abuja
Teaching Hospital, Gwagwalada, Abuja FCT, Nigeria.
Selowo
Temitope Toluse
Department of Chemical Pathology, Benue State
University Teaching Hospital, Makurdi, Nigeria.
Mbwas
Isaac Mashor
Morbid Anatomy Department, Bingham University
Teaching Hospital, Jos, Nigeria.
Please see the
book here: https://doi.org/10.9734/bpi/mono/978-81-973195-5-6/CH3
No comments:
Post a Comment